Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rehabilitation Effect of PP6M in Chinese Patients with Schizophrenia
ChiCTR2500106693Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Non-recurring rate at week 48. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2500106693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106693.